IGF-1 Suppresses Bim Expression in Multiple Myeloma Via Epigenetic and Posttranslational Mechanisms
Overview
Authors
Affiliations
Insulin-like growth factor-1 (IGF-1) is an important growth and survival factor in multiple myeloma (MM). Here, we demonstrate that IGF-1 induces significant down-regulation of the proapoptotic BH3-only protein Bim in MM cells. Reduced Bim levels by RNA interference (RNAi) protected cells from drug-induced cell death. The IGF-1-mediated down-regulation of Bim was the result of (1) reduced transcription by activation of the Akt pathway and inactivation of the transcription factor FoxO3a, (2) increased proteasome-mediated degradation of the Bim extra-long protein by activation of the mitogen-activated protein kinase pathway, and (3) epigenetic regulation of both the Bim and the FoxO3a promoter. Treatment of cells with the histone deacetylase inhibitor LBH589 resulted in a clear up-regulation in the expression of Bim. Furthermore, the methylation inhibitor 5-aza-2'deoxycytidine (decitabine) significantly increased the effects of LBH589. On IGF-1 treatment, the Bim promoter region was found to be unmethylated, whereas chromatin immunoprecipitation analysis of the IGF-1-treated cells showed both a reduced histone H3 tail Lys9 (H3K9) acetylation and an increased H3K9 dimethylation, which contributed actively to its silencing. These data identify a new mechanism in the IGF-1-dependent survival of MM cells and emphasize the need for IGF-1-targeted drug therapy.
Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy.
Nwabo Kamdje A, Dongmo Fogang H, Mimche P Front Mol Med. 2024; 4:1426454.
PMID: 39308891 PMC: 11412843. DOI: 10.3389/fmmed.2024.1426454.
Yoshimura A, Horinaka M, Yaoi T, Ono H, Itoh K, Yamada T Br J Cancer. 2024; 131(2):361-371.
PMID: 38822146 PMC: 11263561. DOI: 10.1038/s41416-024-02727-2.
Fan R, Satilmis H, Vandewalle N, Verheye E, de Bruyne E, Menu E Blood Cancer J. 2023; 13(1):188.
PMID: 38110349 PMC: 10728073. DOI: 10.1038/s41408-023-00962-z.
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar M, Kim H, Kim D Signal Transduct Target Ther. 2023; 8(1):455.
PMID: 38105263 PMC: 10725898. DOI: 10.1038/s41392-023-01705-z.
Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition.
To K, Chow J, Cheung K, Cho W ACS Pharmacol Transl Sci. 2023; 6(10):1531-1543.
PMID: 37854628 PMC: 10580381. DOI: 10.1021/acsptsci.3c00202.